Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.
All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).
All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.
All participants must have adequate organ function.
Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.

Exclusion Criteria:

All participants with non-secretory MM
All participants with known auto-immune disease
All participants with history of life-threatening toxicity related to prior immune therapy.
All participants with active graft versus host disease after allogeneic stem cell transplantation.
All participants with active, unstable cardiovascular function.
All participants with active infection requiring systemic therapy.
All participants with hypersensitivity to any of the treatments.
All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.